CA3166331A1 - Salts and crystalline forms of a taar1 agonist - Google Patents

Salts and crystalline forms of a taar1 agonist

Info

Publication number
CA3166331A1
CA3166331A1 CA3166331A CA3166331A CA3166331A1 CA 3166331 A1 CA3166331 A1 CA 3166331A1 CA 3166331 A CA3166331 A CA 3166331A CA 3166331 A CA3166331 A CA 3166331A CA 3166331 A1 CA3166331 A1 CA 3166331A1
Authority
CA
Canada
Prior art keywords
hydrochloric acid
disorders
acid salt
methyl
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3166331A
Other languages
English (en)
French (fr)
Inventor
Kirsten Andrea GRAESER
Urs Schwitter
Frank Stowasser
Florence Nicole Antoinette TIXERONT
Rene Trussardi (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3166331A1 publication Critical patent/CA3166331A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3166331A 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist Pending CA3166331A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
EP20164069.5 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Publications (1)

Publication Number Publication Date
CA3166331A1 true CA3166331A1 (en) 2021-09-23

Family

ID=69846246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3166331A Pending CA3166331A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Country Status (13)

Country Link
US (1) US12692256B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121428B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023517729A (cg-RX-API-DMAC7.html)
KR (1) KR20220155575A (cg-RX-API-DMAC7.html)
CN (1) CN115279752A (cg-RX-API-DMAC7.html)
AU (1) AU2021238632A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016746A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166331A1 (cg-RX-API-DMAC7.html)
ES (1) ES3044409T3 (cg-RX-API-DMAC7.html)
IL (1) IL294301A (cg-RX-API-DMAC7.html)
MX (1) MX2022010794A (cg-RX-API-DMAC7.html)
TW (1) TWI874616B (cg-RX-API-DMAC7.html)
WO (1) WO2021185878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119654138A (zh) * 2022-08-12 2025-03-18 豪夫迈·罗氏有限公司 包含5-乙基-4-甲基-n-[4-[(2s)吗啉-2-基]苯基]-1h-吡唑-3-甲酰胺的药物组合物
TW202444712A (zh) * 2023-04-28 2024-11-16 大陸商江蘇豪森藥業集團有限公司 一種嗎啉雜環類化合物的鹽及其製備方法和應用
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
RS60825B1 (sr) * 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a

Also Published As

Publication number Publication date
EP4121428B1 (en) 2025-08-13
EP4121428C0 (en) 2025-08-13
WO2021185878A1 (en) 2021-09-23
US20230120311A1 (en) 2023-04-20
MX2022010794A (es) 2022-09-27
TWI874616B (zh) 2025-03-01
CN115279752A (zh) 2022-11-01
KR20220155575A (ko) 2022-11-23
US12692256B2 (en) 2026-07-28
JP2025166092A (ja) 2025-11-05
TW202140466A (zh) 2021-11-01
AU2021238632A1 (en) 2022-07-14
ES3044409T3 (en) 2025-11-26
BR112022016746A2 (pt) 2022-10-11
EP4121428A1 (en) 2023-01-25
JP2023517729A (ja) 2023-04-26
IL294301A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US20230120311A1 (en) Salts and crystalline forms of a taar1 agonist
CN103958469B (zh) 一种新的普利多匹定盐酸盐多晶型形态
JP6995043B2 (ja) リジン特異的デメチラーゼ-1の阻害剤を含む組成物
AU2021200314B2 (en) Crystalline compounds
EP4261212A1 (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
AU2018303293B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
JP5997162B2 (ja) アプレピタントl−プロリン組成物および共結晶
US20230322657A1 (en) Crystalline edg-2 receptor antagonist and methods of making
HK40074347A (en) Salts and crystalline forms of a taar1 agonist
US11643415B1 (en) Rabeximod compounds
EP4553078A1 (en) 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
HK40077679A (en) Crystalline compounds
JP2025527600A (ja) グルコシルセラミド合成酵素阻害薬の結晶形及びその使用
CA3255634A1 (en) CRYSTALLINE FORMS OF 4-[(5-CHLOROPYRIDIN-2-YL)METHOXY]-1-[3-(PROPAN-2-YL)-1H,2H,3H,4H,5H-[1,4]DIAZEPINO[1,7-A]INDOL-9-YL]-1,2-DIHYDROPYRIDIN-2-ONE AND THEIR SALTS, THEIR PREPARATION PROCESS AND THEIR USES
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
HK40003818A (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof
HK1187554B (en) Aprepitant l-proline composition and cocrystal

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250225

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250305

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250305

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250317

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260313

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260806